Medical monitoring is undergoing a fundamental shift as clinical trials become more complex, decentralized, and data intensive.
Sponsors must now balance speed, data quality, and patient safety while meeting evolving regulatory expectations under ICH E6(R3) and FDA risk-based monitoring guidance. The focus is moving from retrospective oversight to a proactive, risk-based medical monitoring approach that leverages data, AI, and cross-functional collaboration to improve decision-making and trial performance.
Read our guide to explore more about:
- How medical monitoring is evolving under ICH E6(R3) and risk-based oversight
- How data, AI, and centralized monitoring enable proactive risk management
- How decentralized and complex trials demand real-time clinical oversight
- How cross-functional collaboration accelerates decision-making and trial efficiency